Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.
Salard, D
Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes. [electronic resource] - Journal of clinical immunology May 1998 - 223-34 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
0271-9142
10.1023/a:1020587123523 doi
Cell Line
Diphtheria Toxin--pharmacology
Drug Synergism
Humans
Interleukin-1--pharmacology
Interleukin-2--pharmacology
Lymphocytes--drug effects
Mycosis Fungoides--blood
Receptors, Interleukin-2--drug effects
Recombinant Fusion Proteins--pharmacology
Sezary Syndrome--blood
T-Lymphocytes--drug effects
Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes. [electronic resource] - Journal of clinical immunology May 1998 - 223-34 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
0271-9142
10.1023/a:1020587123523 doi
Cell Line
Diphtheria Toxin--pharmacology
Drug Synergism
Humans
Interleukin-1--pharmacology
Interleukin-2--pharmacology
Lymphocytes--drug effects
Mycosis Fungoides--blood
Receptors, Interleukin-2--drug effects
Recombinant Fusion Proteins--pharmacology
Sezary Syndrome--blood
T-Lymphocytes--drug effects